Marc Beer, by way of his startup Renova Inc, plans to start beginning work on various pelvic floor products following some $32 million Series B round in addition to $10 million used on business ventures.
The medtech business has plans to build a wide range of necessary diagnostic and therapeutic items required for the treatment of various pelvic floor disorders such as urinary incontinence; a disorder afflicting roughly 250 million women across the globe.
Renovia has several investors and one of them, The Longwood Fund which is an investing firm that specializes in healthcare, became part of the Series B round spearheaded by Perceptive Advisors and Ascension Ventures (These companies are based in New York and Missouri, respectively). The funds given will be used for what will ultimately be the creation of four new and innovative therapeutic and diagnostic devices, one of which include a massive update of Renovia’s Leva product.
Marc Beer started that it was an honor to be backed by those in the healthcare industry who are truly interested in making a genuine change alongside Renovia for the betterment of millions of women worldwide who suffer from pelvic floor disorders. He hopes that in teaming up with these investors, sharing technological expertise and seeking better means of treatment for these women, there will be a more comprehensive grasp of pelvic floor disorders and what could be done to drive the costs of healthcare down considerably.
Renovia CEO, Chairman and co-founder Marc Beer has experience beyond Renovia as he has been the CEO of ViaCell, biotech firm that handles the blood stem cells of the umbilical cord, back in 2000. Thanks to Marc and his stellar management of the business, it became over 300 employees strong. His 25 years plus years of experience with the biotech, diagnostic and device fields show his dedication to his career beyond simply for the same of money.
Marc holds a position as the premiere chairman of the Good Start Genetics Compensation Committee and its director’s board. In addition to this, he is the Minerva Neurosciences Inc Audit Committee’s founding chairman and one of its esteemed members. Not to mention he is part of the Business Advisory Council of Miami University and the Graduate Studies Research of Notre Dame.